Clinical trial
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.
NCT00738829 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.
- Lead sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- January 31, 2012
- Enrollment
- 45 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.